WallStreetZenWallStreetZen
NASDAQ: SYRS

How to Buy Syros Pharmaceuticals Stock

Open Broker Account

Syros Pharmaceuticals Inc

Syros Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines.

Syros Pharmaceuticals stock last closed at $3.95, down 0.25% from the previous day, and has decreased 89.15% in one year. It has underperformed other stocks in the Biotechnology industry by 0.54 percentage points. Syros Pharmaceuticals stock is currently +12.22% from its 52-week low of $3.52, and -90.88% from its 52-week high of $43.30.

As of Dec 1, 2022, there are 20.23M SYRS shares outstanding. The market value of SYRS is $79.89M. In the last 24 hours, 102,832 SYRS shares were traded.

How to Buy Syros Pharmaceuticals Stock

Wondering how to invest in Syros Pharmaceuticals stock? Here's how.
  1. Choose where to buy Syros Pharmaceuticals stock: You need to choose a stock brokerage, but don't worry - we've tested dozens of stock brokerages and apps to help you choose where to buy Syros Pharmaceuticals stock.
  2. Create a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've identified. It's the best place to buy SYRS stock.
  3. Deposit funds into your brokerage account: Choose your payment method and add your information.
  4. Analyze Syros Pharmaceuticals stock: The Syros Pharmaceuticals ticker symbol is SYRS. Is Syros Pharmaceuticals stock a good investment? Should you buy shares of SYRS? How do SYRS's underlying business fundamentals look? Do top analysts think Syros Pharmaceuticals is a good buy? Why has SYRS's stock price moved recently? (Hint: Our stock research tools can help you understand if SYRS is a good stock to buy).
  5. Place your SYRS trade: Decide if you will purchase SYRS shares at the current market price or use a limit order to purchase SYRS shares at a particular price.
  6. Keep an eye on your SYRS position: Create a watchlist to keep tabs on your position in Syros Pharmaceuticals stock.

Step 1: Choose where to buy Syros Pharmaceuticals stock

You need an online brokerage account in order to access the NASDAQ market and buy SYRS stock.

A brokerage account is an investment account that allows you to buy and sell a number of investments, including stocks, bonds, mutual funds, and ETFs.

Our recommended brokerage: eToro

Based on our research, eToro is the best online stock brokerage. Here's why:

  • Invest in stocks with 0% commissions: Invest without paying trading commissions.
  • Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
  • Access to global markets: From Tech to Industrials, New York to London — you can fill your portfolio with stocks from the world's leading stock exchanges.
  • Social investing: eToro boasts a community with more than 20 million users worldwide. Talk to, learn from, and copy the unique crypto portfolios of other investors.
  • Security: eToro is a regulated and licensed fintech leader.
  • Buy other assets: Such as ETFs and cryptos.

Get $10 towards your purchase of stock by creating an account with eToro today.

Open eToro Account

Step 2: Create a brokerage account

Now that you've chosen the best brokerage, you need to fill out some personal information so you are able to buy SYRS today.

How to Set Up a New Account on eToro

  1. Click here to get started.
  2. Enter your personal details to create a new brokerage account.
  1. Submit your info by pressing the "Create Account" button.
Get started with eToro today

Step 3: Deposit funds into your brokerage account

Check out the tutorial below for more details transferring funds into your new brokerage account.

Get started with eToro today

Step 4: Analyze Syros Pharmaceuticals stock

It's critical to research stocks before you buy, so you actually understand the risk and upside.

Syros Pharmaceuticals Metrics

SYRS Price
$3.95
1w %
-4.59%
1y %
-89.15%
5y %
-97.44%
P/E
-0.24x
P/B
0.62x
P/S
1.59x
PEG
N/A
Revenue
$23.44M
Earnings
-$113.69M
Fore. Rev. Growth
25.34%
Fore. Earn. Growth
N/A
Market Cap
$79.89M
Next Earnings
N/A
Next Dividend
N/A

Syros Pharmaceuticals Fundamentals

WallStreetZen was designed to help everyday investors do better fundamental analysis in minutes instead of hours.

You can see all of the due diligence checks on SYRS's stock page.

Is SYRS stock properly valued?

You can use a variety of different financial metrics, analyses, models, and charts to gauge SYRS's true value.

Using relative valuations ratios:

  • SYRS could be undervalued based on its P/B ratio of 0.62x, relative to Biotechnology industry P/B ratio of 4.98x

You can do additional valuation research on SYRS's stock here.

SYRS Financial Overview

Passed Financial Due Diligence Checks:

  • SYRS has $247.57M in cash and short term investments. This is sufficient to cover its annual cash burn of $115.76M.
  • SYRS has cash burn of 115763000. It has sufficient cash and short-term investments to cover this for at least one year.
  • There are more short-term assets than short-term liabilities on the SYRS balance sheet.
  • There are more short-term assets than long-term liabilities on the SYRS balance sheet.

Failed Financial Due Diligence Checks:

  • SYRS profit margin has gone down from -434.3% to -485.1% in the past year.
  • Total SYRS debt is higher than 5 years ago, relative to shareholder equity.
  • SYRS has a relatively high debt to equity ratio of 1.2.

Is it a good time to buy SYRS stock?

Out of 4 sell side analysts who research SYRS, the consensus analyst rating on SYRS is a Strong Buy

Should I buy or sell SYRS stock?

Based on 4 analysts offering ratings for Syros Pharmaceuticals Inc.
Strong Buy
Strong Buy
1 analysts 25%
Buy
3 analysts 75%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Latest SYRS Analyst Forecasts

Jason Butler, a bottom 9% analyst from JMP Securities maintains SYRS with a buy rating and lowers their SYRS price target from $40.00 to $16.00, on Nov 15, 2022.

Mark Breidenbach, a bottom 19% analyst from Oppenheimer maintains SYRS with a buy rating and lowers their SYRS price target from $30.00 to $15.00, on Nov 15, 2022.

Andrew Fein, a bottom 9% analyst from HC Wainwright & Co. maintains SYRS with a buy rating and raises their SYRS price target from $6.00 to $20.00, on Nov 15, 2022.

Matt Cross, a bottom 34% analyst from Alliance Global Partners maintains SYRS with a strong buy rating and lowers their SYRS price target from $14.00 to $10.00, on May 17, 2022.

You can dive deeper into what analysts are forecasting on the Syros Pharmaceuticals stock forecast page.

Metrics for Advanced SYRS Traders

SMA10
4.03
SMA20
3.99
SMA50
4.86
SMA100
6.59
SMA200
8.34
MACD
-0.24
MACD Signal
-0.31
MACD Histogram
0.07
RSI
42.7
Stochastic %K
41.02
Stochastic %D
40.33
StochRSI %K
72.06
StochRSI %D
68.71

How is SYRS performing as a company?

Last year, SYRS revenue was $23.44M. During the past 5 year, SYRS's revenue has gone up by 75.24% per year. This was slower than the Biotechnology industry average of 81.34%.

Dig into SYRS's earnings and revenue performance here.

What are SYRS executives and large shareholders up to?

Over the past 12 months, insiders at SYRS have sold more shares than they have bought.

Timothy Tyson, Director of SYRS, was the latest SYRS insider to buy. They bought $89,180.00 worth of SYRS shares on Sep 30, 2022.

Dig into more about who owns SYRS shares here.

Does SYRS stock generate passive income?

No, Syros Pharmaceuticals doesn't provide an income stream by paying out dividends.

What do other traders have to say about SYRS?

One of the primary reasons eToro is our top-rated brokerage is because of its social trading community.

Click below to see what other community members have to say.

Step 5: Place your SYRS trade

You have two main options:

  • Market order: A market order is an order to buy or sell a stock at the best available price.
    Market orders are generally sufficient.
  • Limit order: A limit order lets you buy or sell a stock at a specific price (or better).
    If you want to ensure you're buying or selling at a particular dollar amount limit, place a limit order.

Press the Open Trade button and your broker will place the order.

If you require more help buying stocks on eToro, click the helpful video below:

Open eToro Account

Step 6: Keep an eye on your SYRS position

Now that you own some SYRS stock, you'll want to keep up with your investment.

Start a watchlist to see the latest developments about your SYRS stock.

SYRS Feed

How to Buy Stock in Syros Pharmaceuticals

To summarize, here are the 6 steps to buy stock in Syros Pharmaceuticals:

  1. Choose where to buy Syros Pharmaceuticals stock
  2. Create a brokerage account
  3. Deposit funds into your brokerage account
  4. Analyze Syros Pharmaceuticals stock
  5. Place your SYRS trade
  6. Keep an eye on your SYRS position

If you require a brokerage, eToro is our recommended option.

Get Started with eToro Today

If you would like to monitor your investment in Syros Pharmaceuticals, create a watchlist today.

NASDAQ: SYRS
$3.95-0.01 (-0.25%)
Updated Dec 1, 2022
Open eToro Account
NASDAQ: SYRS
$3.95-0.01 (-0.25%)
Updated Dec 1, 2022
Open eToro Account

FAQ

How much does it cost to buy one Syros Pharmaceuticals share?

As of Dec 1, 2022, it costs $3.95 to buy one share of Syros Pharmaceuticals stock.

Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $1, you can buy 0.253 shares of SYRS.

Get Started with eToro Today

Is now a good time to buy Syros Pharmaceuticals stock?

According to 4 Wall Street analysts who monitor Syros Pharmaceuticals, their consensus recommendation is to buy Syros Pharmaceuticals stock.

What is the best way to buy Syros Pharmaceuticals stock?

The best way to buy Syros Pharmaceuticals stock is within a brokerage account on eToro.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.